Dutch biotech uniQure recently announced that its novel gene therapy, AMT-130 (ifezuntirgene inilparvovec), demonstrated ...
Biosciences presented new data from the open-label KINECT-HD2 study demonstrating an established long-term safety profile, tolerability and sustained improvements in chorea severity through three ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile, tolerability and sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback